Drug Profile
ELX1 007
Alternative Names: ELX1-007; ELX1.007; FirstCoverLatest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Elanix Biotechnologies
- Developer Elanix Biotechnologies; University Hospital of Lausanne
- Class Biological factors; Cytokines; Growth factors; Skin disorder therapies; Tissue extracts
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Wounds
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Wounds in Switzerland (Topical, Gel)
- 06 Sep 2016 Clinical trials in Wounds in Switzerland (Topical)
- 06 Sep 2016 ELX1 007 receives Advanced Therapeutic Medicinal Product designation in Europe before September 2016 (Elanix Biotechnologies pipeline, September 2016)